Upfront Riociguat and Ambrisentan Combination Therapy for Pulmonary Arterial Hypertension: A Safety and Efficacy Pilot Study
Principal Investigator
John SwistonOverview
Study Start/End
Mar 8, 2019 to Dec 31, 2019Locations
Diamond Health Care CentreName/Title
Mami Okada, Research CoordinatorPhone
604-875-4111 ext.69831Email Address
mami.okada@vch.caPurpose of Study
The purpose of this study is to evaluate the safety and efficacy of first-line combination therapy using riociguat with ambrisentan in patients with Pulmonary Arterial Hypertension (PAH).
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.